HLA-G is differentially expressed in thyroid tissues

Thyroid

Volumn 24, Issue 3, 2014, Pages 585-592

  De Figueiredo Feitosa, Nathalie Lobo ^a   De Oliveira Crispim, Janaina Cristina ^b   Zanetti, Bruna Riedo ^a   Magalhães, Patrícia Kunzle Ribeiro ^a   Soares, Christiane Pienna ^a   Soares, Edson Garcia ^a   Neder, Luciano ^a   Donadi, Eduardo Antonio ^a   Maciel, Léa Maria Zanini ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HLA G ANTIGEN; THYROGLOBULIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLICULAR ADENOMA; FOLLOW UP; GOITER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RECURRENT DISEASE; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICLE CELL; THYROID GLAND; THYROID HYPERPLASIA; THYROID TUMOR; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; AGED; CARCINOMA, PAPILLARY; FEMALE; GOITER; HLA-G ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84896788509     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0246     Document Type: Article

References (44)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
2. National Cancer Institute 2013. Surveillance, Epidemiology and End Results Program. Available at: http://seer.cancer .gov (accessed October 30, 2013).
3. Kilfoy BA, Zheng T, Holford TR Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, Zhang Y 2009 International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20:525-531.
4. Pacini F, Schlumberger M 2006 Thyroid Tumors. Third edition. Éditions Nucléon, Paris.
5. Carosella ED, Horuzsko A 2007 HLA-G and cancer. Semin Cancer Biol 17:411-412.
6. King A, Hiby SE, Gardner L, Joseph S, Bowen JM, Verma S, Burrows TD, Loke YW 2000 Recognition of trophoblast HLA class I molecules by decidual NK cell receptors - a review. Placenta 21:S81-85.
7. Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, Geraghty DE 2003 Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 171:1376-1384.
8. Fujii T, Ishitani A, Geraghty DE 1994A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 153:5516-5524.
9. Paul P, Cabestre FA, Ibrahim EC, Lefebvre S, Khalil-Daher I, Vazeux G, Quiles RM, Bermond F, Dausset J, Carosella ED 2000 Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA -G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 61:1138-1149.
10. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED 1998 HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 95:4510-4515.
11. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H 2005 Monocytederived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J. Neuroimmunol 159:155-164.
12. Crispim JCO, Duarte RA, Soares CP, Costa R, Silva JS, Mendes-Junior CT, Wastowski IJ, Faggioni LP, Saber LT, Donadi EA 2008 Human leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection. Transplant Immunol 18:361-367.
13. LeMaoult J, Le Discorde M, Rouas-Freiss N, Moreau P, Menier C, McCluskey J, Carosella ED 2003 Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 62:273-284.
14. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N 2008 HLA-G: from biology to clinical benefits. Trends Immunol 29:125-132.
15. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED 2005 HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65:10139-10144.
16. Zilberman S., Schenowitz C, Agaugué S, Favier B, Riteau B, Rouzier R, Carosella ED, Rouas-Freiss N, Menier C 2012 HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment. Eur J Immunol 42:1599-1608.
17. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F 2003 Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8 + cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33:125-134.
18. Riteau B, Menier C, Khalil-Daher I, Khalil-Daher I, Sedlik C, Dausset J, Rouas-Freiss N, Carosella ED 1999 HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 43:203-211.
19. Bainbridge D, Ellis SA, Sargent IL 2000 HLA-G suppresses proliferation of CD4 T-lymphocytes. J Reprod Immunol 48:17-26.
20. Yie SM, and Hu Z 2011 Human Leukocyte Antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol Histopathol 26:409-420.
21. Souto FJ, Crispim JC, Ferreira SC, da Silva AS, Bassi CL, Soares CP, Zucoloto S, Rouas-Freiss N, Moreau P, Martinelli AL, Donadi EA 2011 Liver HLA-G expression is associated with multiple clinical and histopathological forms of chronic hepatitis B virus infection. J Viral Hepat 18:102-105.
22. Kemp EH, Metcalfe RA, Watson PF, Weetman AP 2003 HLA-G does not have a pathophysiological role in Graves's disease. J Clin Pathol 56:475-477.
23. Dardano A, Rizzo R, Polini A, Stignani M, Tognini S, Pasqualetti G, Ursino S, Colato C, Ferdeghini M, Baricordi OR, Monzani F 2012 Soluble human leukocyte antigen-G and its insertion/deletion polymorphism in papillary thyroid carcinoma: novel potential biomarkers of disease? J Clin Endocrinol Metab 97:4080-4086.
24. Nunes LM, Ayres FM, Francescatonio ICM, Saddi VA, Avelino MAG, Alencar RCG, Silva RC, Meneghini AJ, Wastowski IJ 2013 Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer. Hum Immunol 74:447-451.
25. Rodriguez JA, Galeano L, Palacios DM, Gómez C, Serrano ML, Bravo MM, Combita AL. 2012 Altered HLA class I and HLA-G expression is associated with IL-10 expression in patients with cervical cancer. Pathobiology 79:72-83.
26. Mouillot G, Marcou C, Zidi I, Guillard C, Sangrouber D, Carosella ED, Moreau P 2007 Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 68:277-285.
27. Gonzá lez A, Rebmann V, LeMaoult J, Horn P, Carosella E, Alegre E 2012 The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci 49: 63-84.
28. Elliott RL, Jiang XP, Phillips JT, Barnett BG, Head JF 2011 Human leukocyte antigen G expression in breast cancer: role in immunosuppression. Cancer Biother Radiopharm 26:153-157.
29. Menier C, Prevot S, Carosella ED, Rouas-Freiss N 2009 Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum Immunol 70:1006-1009.
30. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM 2007 Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 20:375-383.
31. Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM 2007 Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 128: 1002-1009.
32. Ishigami S, Natsugoe S, Miyazono F, Nakajo A, Tokuda K, Matsumoto M, Okumura H, Douchi T, Hokita S, Aikou T 2006 HLA-G expression in gastric cancer. Anticancer Res 26:2467-2472.
33. Gan LH, Huang LF, Zhang X, Lin A, Xu DP, Wang Q, Wang TJ, Yan WH 2010 Tumor-specific up regulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma. Hum Immunol 71:899-904.
34. Hanak L, Slaby O, Lauerova L, Kren L, Nenutil R, Michalek J 2009 Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy. Med Sci Monit 15:638-643.
35. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED 2007 Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 109:2040-2048.
36. Liotti F, Visciano C, Melilo RM 2012 Inflammation in thyroid oncogenesis. Am J Cancer Res 2:286-297.
37. Burrows N, Resch J, Cowen RL, Wasielewski R, Hoang-Vu C, West CM, Williams KJ, Brabant G 2010 Expression of hypoxia-inducible factor 1 alfa in thyroid carcinomas. Endocr Relat Cancer 17:61-72.
38. Pufnock JS, Rothstein JL 2009 Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J Immunol 182:5498-5506.
39. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesù G, De Maria R, Stassi G 2006 Autocrine production of interleukine-4 and interleukine-10 is required for survival and growth of thyroid cancer cells. Cancer Res 66:1491-1499.
40. Kobawala TP, Patel GH, Gajjar DR, Patel KN, Thakor PB, Parekh UB, Patel KM, Shukla SN, Shah PM 2011 Clinical utility of serum ilterleukine-8 and interferon-alpha in thyroid disease. J Thyroid Res 2011:270149.
41. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670.
42. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, Torchio B, Papotti MG 2004 Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100:950-957.
43. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM 2013 Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 23:1401-1407.
44. Kloos RT 2008 Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. J Clin Endocrinol Metab 93:1519-1525.